Forest Laboratories, Royalty Pharma, Apotex, Hetero Drugs, Lupin, Mylan, Par Pharmaceutical musculoskeletal news

Forest and Royalty filed suits in the U.S. District Court for the District of Delaware alleging that the generic companies are infringing patents covering Savella milnacipran from Forest to treat fibromyalgia. Forest and Royalty Pharma said the generic companies' ANDA submissions for generic versions of Savella infringe U.S. Patents Nos. 6,602,911; 7,888,342; and 7,994,220. Forest licenses the patents from Royalty Pharma. The '911 patent, which expires in January 2023, and the '342 patent, which expires in November 2021, cover methods of use of Savella. The '220 patent, which expires in September 2029, relates to the required dosing schedule for Savella. ...